Cyllene Therapeutics (formerly known as EG 427) Raises €33 Million Series C Financing to Advance Clinical Development of EG110A and Pipeline ExpansionParis, July 07, 2026 (GLOBE NEWSWIRE) -- Cyllene Therapeutics, formerly known as EG 427, today announced the successful closing of a €33 million Series C financing led by new investors GordonMD Global Investments® LP (“GordonMD”) and M Ventures. Existing investors including Andera Partners SAS, Bpifrance Investissement through its InnoBio 3 Fund, L.P. and Lamond Ventures LLC also participated in the round.
